Skip to main content

Kathryn B. McKenzie

Equibles does not estimate personal net worth.

About Kathryn B. McKenzie

Kathryn B. McKenzie was last confirmed as CFO at Neogenomics Inc (NEO) in a filing dated April 14, 2022. The proxy statement of Neogenomics Inc reports total compensation of $1,034,616 for Kathryn B. McKenzie in fiscal 2020, including a base salary of $359,616. Disclosed compensation is on record for 4 fiscal years. Kathryn B. McKenzie has spoken on 7 earnings calls across 1 company, most recently for Neogenomics Inc on November 4, 2021. The companies whose calls Kathryn B. McKenzie spoke on are classified in the Healthcare sector.

Kathryn B. McKenzie on recent calls

“Revenue excluding COVID-19 PCR testing grew 12% year-over-year to $121 million in quarter three. Clinical revenues of $102 million represented 11% year-over-year growth excluding COVID-19 PCR testing.”
CFO, Neogenomics Inc Q3 FY2021 Earnings Call ·
“Second quarter clinical division revenue grew 37% year-over-year, driven by a strong bounce back in clinical volume compared to the depressed volumes during the initial wave of the pandemic in the second quarter last year.”
CFO, Neogenomics Inc Q2 FY2021 Earnings Call ·
“Despite the impact of the ongoing pandemic, total revenue in Q1 grew 9% year-over-year to $116 million. Importantly, our core oncology revenues increased 7% year-over-year, driven by strong growth in NGS, Pharma Services and Informatics.”
CFO, Neogenomics Inc Q1 FY2021 Earnings Call ·
“As Doug highlighted, overall revenue grew 18% year-over-year to $126 million. Importantly, our core oncology revenues increased 10% year-over-year driven by strong growth in NGS, Pharma Services, and Informatics.”
CFO, Neogenomics Inc Q4 FY2020 Earnings Call ·
“As Doug highlighted, overall revenue grew 44% sequentially and 20% year-over-year to $125 million. Clinical Division revenues increased 17% year-over-year, boosted significantly by the contribution from COVID-19 PCR testing.”
CFO, Neogenomics Inc Q3 FY2020 Earnings Call ·

Affiliation history

  • Neogenomics Inc (NEO)

    CFO

    Proxy statement

    Start not stated–2022-04-14

    Last confirmed by a filing; no departure on record

Company network

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2020 Neogenomics Inc (NEO) $359,616 $1,034,616
2019 Neogenomics Inc (NEO) $250,000 $524,844
2018 Neogenomics Inc (NEO) — —
2017 Neogenomics Inc (NEO) — —

Recent activity